首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Diabetes Technology & Therapeutics

Diabetes Technology & Therapeutics杂志,由Mary Ann Liebert Inc.出版,于1999年创刊,Monthly,出版语言English,ISSN:1520-9156,E-ISSN:1557-8593。

投稿咨询
Diabetes Technology & Therapeutics
Diabetes Technology & Therapeutics
Diabetes Technology & Therapeutics
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
7.4
CiteScore
10.5
期刊收录
SCI、SCIE

Diabetes Technology & Therapeutics(中文译名:《糖尿病技术与治疗》),ISSN:1520-9156,EISSN:1557-8593,是Mary Ann Liebert Inc.出版的国际性学术期刊,创刊于1999年,以Monthly形式稳定发行,2026年总发文量约160篇。该刊采用非OA开放访问,学科归属为医学 - 内分泌学与代谢。该刊是医学、内分泌学与代谢领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达7.4,2025年期刊CiteScore为10.5,2025年期刊自引率约18.9%,在中科院期刊分区体系中位列医学大类2区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Diabetes Technology & Therapeutics长期聚焦医学、内分泌学与代谢及相关产业的技术应用前沿,平均审稿周期一般,3-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、内分泌学与代谢领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAGERMANY (FED REP GER)、England、Italy、Spain、France、Russia等为核心发文国家与地区;UNIVERSITY OF COLORADO SYSTEMHARVARD UNIVERSITY、STANFORD UNIVERSITY、UNIVERSITY OF VIRGINIA、UNIVERSITY OF CALIFORNIA SYSTEM、IMPERIAL COLLEGE LONDON、UNIVERSITY OF PADUA等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ENDOCRINOLOGY & METABOLISM 内分泌学与代谢
1区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ENDOCRINOLOGY & METABOLISM 内分泌学与代谢
2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ENDOCRINOLOGY & METABOLISM 内分泌学与代谢
2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ENDOCRINOLOGY & METABOLISM SCIE Q1 21 / 198

89.6

学科:ENDOCRINOLOGY & METABOLISM SCIE Q1 16 / 198

92.17

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ENDOCRINOLOGY & METABOLISM SCIE Q1 24 / 193

87.8

学科:ENDOCRINOLOGY & METABOLISM SCIE Q1 18 / 193

90.93


中国学者近期发文

1
ASSOCIATION BETWEEN LATE SLEEP TIMING AND INCREASED HYPOGLYCEMIA RISK IN GESTATIONAL DIABETES MELLITUS: INSIGHTS FROM CONTINUOUS GLUCOSE MONITORIN

Author:Zhu, Hui; Li, Yuqiong; Ji, Lindan; Xu, Jin

Journal: DIABETES TECHNOLOGY & THERAPEUTICS. 2026; Vol. 28, Issue , pp. 359S-360S. DOI:

2
ASSOCIATIONS BETWEEN ESTIMATED CARDIORESPIRATORY FITNESS AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ELDERLY PATIENT WITH TYPE 2 DIABETE

Author:Zhou, Lili

Journal: DIABETES TECHNOLOGY & THERAPEUTICS. 2026; Vol. 28, Issue , pp. 151S-151S. DOI:

3
EFFICACY AND SAFETY OF IGLARLIXI VS IDEGASP BY BASELINE AGE AND DISEASE DURATION IN CHINESE PEOPLE WITH T2D: POST-HOC ANALYSES OF THE SOLI-D STUD

Author:Zhang, Saichun; Cheng, Yu; Hu, Ying; Li, Bing; Alvarez, Agustina; Lauand, Felipe; Melas-Melt, Lydie; Zhang, Jie; Du, Qin; Kang, Lei; Mabunay, Maria Aileen; Mu, Yiming; Gu, Weijun

Journal: DIABETES TECHNOLOGY & THERAPEUTICS. 2026; Vol. 28, Issue , pp. 349S-349S. DOI:

4
EFFICACY AND SAFETY OF INSULIN GLARGINE 300 U/ML IN T2D BY BASELINE DISEASE DURATION IN CHINA: AN INITIATION STUDY POST HOC ANALYSI

Author:Zhang, Qiu; Chen, Liming; Wen, Binhong; Liu, Haixia; Wu, Hongmei; Duan, Binhong; Shu, Hongyan; Wu, Xiaohong; Liu, Weiwei; Du, Qin; Kang, Lei; Zhang, Minlu

Journal: DIABETES TECHNOLOGY & THERAPEUTICS. 2026; Vol. 28, Issue , pp. 418S-419S. DOI:

5
THE ASSOCIATION OF DIABETIC NEPHROPATHY WITH TIME IN TIGHT RANGE MEASURED BY CONTINUOUS GLUCOSE MONITOR IN PATIENTS WITH TYPE 2 DIABETE

Author:Zhang, Lei; Mo, Wanyu; Li, Wen

Journal: DIABETES TECHNOLOGY & THERAPEUTICS. 2026; Vol. 28, Issue , pp. 381S-382S. DOI:

6
COMPARISON OF THE EFFECTIVENESS IN GLYCEMIC CONTROL IN PATIENTS WITH TYPE 1 DIABETES OF TWO OPEN-SOURCE ARTIFICIAL PANCREAS SYSTEM

Author:Xv, Yanqin; Li, Xianming; Wang, Qin; Zhang, Wenhao; Ding, Yu; Weng, Jianping; Luo, Sihui

Journal: DIABETES TECHNOLOGY & THERAPEUTICS. 2026; Vol. 28, Issue , pp. 392S-393S. DOI:

7
ONE-YEAR EFFECTIVENESS OF REAL-TIME CONTINUOUS GLUCOSE MONITORING AMONG YOUNG PEOPLE WITH DIABETES IN A REALWORLD SETTING IN HONG KON

Author:Wong, Kelly T. C.; Tsang, Atta Y. T.; Ling, James; Kong, Alice; Luk, Andrea O. Y.; Chan, Juliana; Lui, Juliana N. M.; Chow, Elaine; Ma, Ronald C. W

Journal: DIABETES TECHNOLOGY & THERAPEUTICS. 2026; Vol. 28, Issue , pp. 415S-416S. DOI:

8
AI-BASED TONGUE AND FACIAL IMAGE FEATURES AS PREDICTORS OF METABOLIC STATUS IN OBESE AND OVERWEIGHT PATIENTS WITH OR WITHOUT DYSREGULATED GLYCEMI

Author:Wen, Song; Xu, Zhinmin; Ren, Yishu; Li, Fufeng; Zhou, Ligang

Journal: DIABETES TECHNOLOGY & THERAPEUTICS. 2026; Vol. 28, Issue , pp. 442S-443S. DOI:

9
IMPACT OF AURICULAR ACUPUNCTURE AND INTERMITTENT ELECTROACUPUNCTURE ON GLYCEMIC VARIABILITY AND STABILITY IN HOSPITALIZED DIABETIC PATIENTS: A CGMS-BASED TIME-SEGMENTED ANALYSI

Author:Wen, Song; Jin, Jianlan; Liu, Haiyan; Zhou, Ligang

Journal: DIABETES TECHNOLOGY & THERAPEUTICS. 2026; Vol. 28, Issue , pp. 222S-222S. DOI:

10
AI-DRIVEN DIGITAL THERAPEUTIC FOR INSULIN TITRATION DURING INTENSIVE INSULIN THERAPY IN TYPE 2 DIABETES: A SINGLE-ARM TRIA

Author:Wang, Xulin; Zhu, Jiangyu; Wang, Siqi; Luo, Sihui; Weng, Jianping

Journal: DIABETES TECHNOLOGY & THERAPEUTICS. 2026; Vol. 28, Issue , pp. 403S-403S. DOI:


在线咨询

Diabetes Technology & Therapeutics

国际简称:DIABETES TECHNOL THE参考译名:糖尿病技术与治疗

年发文量:160 CiteScore:10.5 是否预警:否 Gold OA文章占比:23.73% 研究类文章占比:95.63%

杂志社联系方式:MARY ANN LIEBERT INC, 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, USA, NY, 10801

Diabetes Technology & Therapeutics